Brief

Shenzhen New Star announced that its controlling shareholder, Chen Xuemin, plans to transfer 100% of its equity in Yandai Investment to Shenzhen Jiatai Zhiyuan Technology Partnership for 557 million yuan. Following this transaction, Chen Xuemin will retain control of the company with 19.18% of the shares, while Jiatai Zhiyuan will indirectly hold 11.97% through Yandai Investment. In a separate announcement, Jiaoda Sinno plans to acquire 60.28% of Beijiao Xintong through a combination of stock issuance and cash payment, with the goal of strengthening its position in the rail transit communication sector. AI

Jiaoda Sinno plans to acquire a 60.28% stake in Beijing Xintongchuanglian Technology, a company specializing in railway communication products. This acquisition aims to strengthen Jiaoda Sinno's market position in the railway sector and diversify its product offerings. The company will also raise additional capital through a private placement to no more than 35 investors. Separately, Zhenbaodao's subsidiary has entered into a strategic agreement with Zhejiang Teres to become the sales agent for their innovative biologic drug TRS005 in China, which is intended for treating certain types of lymphoma. AI